Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA Negotiations End, Approval Process Ongoing

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry still working on ratifying draft commitment letter.


Related Content

Generic User Fee Talks Reach 'Final Wording' But Still Not Done
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods
PDUFA Negotiations: Early Communications, Breakthrough Still On Docket
PDUFA VI: Innovative Trial Design Proposal Includes Modeling, Simulation
PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts